These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25671011)

  • 1. Prescription drug monitoring programs: examining limitations and future approaches.
    Griggs CA; Weiner SG; Feldman JA
    West J Emerg Med; 2015 Jan; 16(1):67-70. PubMed ID: 25671011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combating an Epidemic of Prescription Opioid Abuse.
    Pon D; Awuah K; Curi D; Okyere E; Stern CS
    J Calif Dent Assoc; 2015 Nov; 43(11):673-8. PubMed ID: 26798885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of North Carolina's prescription drug monitoring program on the prescribing behaviors of the state's providers.
    Ringwalt C; Garrettson M; Alexandridis A
    J Prim Prev; 2015 Apr; 36(2):131-7. PubMed ID: 25466768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provider perceptions of system-level opioid prescribing and addiction treatment policies.
    Haffajee RL; French CA
    Curr Opin Psychol; 2019 Dec; 30():65-73. PubMed ID: 30856591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?
    Peckham AM; Fairman KA; Sclar DA
    Expert Opin Drug Saf; 2018 May; 17(5):519-523. PubMed ID: 28985090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combating the prescription painkiller epidemic: a national prescription drug reporting program.
    Shepherd J
    Am J Law Med; 2014; 40(1):85-112. PubMed ID: 24844043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription drug monitoring and dispensing of prescription opioids.
    Brady JE; Wunsch H; DiMaggio C; Lang BH; Giglio J; Li G
    Public Health Rep; 2014; 129(2):139-47. PubMed ID: 24587548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Boxed Warning for Immediate-Release Opioids.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):141-5. PubMed ID: 27301692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Drug Monitoring Programs: Relationships Among Program Awareness, Use, and State Mandates.
    Williams KS; Magalotti S; Schrouder K; Knox M; Feldman L; Ujwal D; Lynch D
    J Pain Palliat Care Pharmacother; 2018; 32(2-3):129-133. PubMed ID: 30198819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Implementation of Prescription Drug Monitoring Programs in the Emergency Department.
    Elder JW; DePalma G; Pines JM
    West J Emerg Med; 2018 Mar; 19(2):387-391. PubMed ID: 29560070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).
    Nelson LS; Perrone J
    JAMA; 2012 Aug; 308(5):457-8. PubMed ID: 22851109
    [No Abstract]   [Full Text] [Related]  

  • 14. Overdose Epidemic, Prescription Monitoring Programs, and Public Health: A Review of State Laws.
    Davis CS; Johnston JE; Pierce MW
    Am J Public Health; 2015 Nov; 105(11):e9-e11. PubMed ID: 26378849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Drug Monitoring Programs Reduce the Misuse of Opioids?
    Natl Bur Econ Res Bull Aging Health; 2017; (2):1-2. PubMed ID: 28591976
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA committee: More restrictions needed on hydrocodone combination products.
    Kuehn BM
    JAMA; 2013 Mar; 309(9):862. PubMed ID: 23462764
    [No Abstract]   [Full Text] [Related]  

  • 17. Prescription drug monitoring programs: Combating prescription drug misuse.
    Gudoski AJ
    Nurse Pract; 2015 Nov; 40(11):28-33; quiz 33-4. PubMed ID: 26474200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings.
    Pauly NJ; Slavova S; Delcher C; Freeman PR; Talbert J
    Drug Alcohol Depend; 2018 Mar; 184():26-32. PubMed ID: 29402676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Opioid Epidemic: AMA's response.
    Harris PA
    Am Fam Physician; 2016 Jun; 93(12):975. PubMed ID: 27304766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.